Understanding Huntington's Disease

Researchers are inching ever closer to a treatment for the inherited neurodegenerative disorder Huntington's disease (HD). Following close on the heels of recent optimistic reports on fetal cell implants1,2 comes a report from Johns Hopkins University that sheds light on a possible mechanism of neuronal destruction in HD.3 The work reveals possible new drug targets. Legendary folksinger Woody Guthrie's fight with HD brought the disease into the public eye in the 1960s. Today, some 30,000 peopl

Written byRicki Lewis
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Legendary folksinger Woody Guthrie's fight with HD brought the disease into the public eye in the 1960s. Today, some 30,000 people in the United States are affected by the late-onset, autosomal dominant condition. Early symptoms--such as anger or depression, repetitive fidgety movements, and a clumsiness and tendency to fall--may go unnoticed for years. Neurological deterioration, reflecting cell death in the brain's striatum, typically continues for 15 to 20 years. HD has left its mark on the recent history of genetics, but has remained frustratingly untreatable. Discovery of a marker in 1983,4 and of the gene in 1993,5 gave affected families the option of predictive testing, but without any treatments that could halt or even slow the disease process.

As one of the first "triplet repeat" disorders to be described, HD is also one of eight "polygln" disorders in which an expanded repeat of the RNA triplet CAG adds extra glutamines ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies